Thomas Broeer elected as new BGMA chair
This article was originally published in Scrip
The British Generic Manufacturers Association (BGMA) has appointed Thomas Broeer, managing director of Kent Pharmaceuticals, as its new chair for the next two years. He replaces Kim Innes, a director at Teva, who will continue for a further year as vice-chair of the association, which is the generic industry's trade body representing more than 90% of the UK supply market. Before taking up the role with Kent, Mr Broeer held senior management roles at Mylan in the UK and Germany.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.